Crinetics Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Crinetics Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Crinetics Pharmaceuticals: 16 sponsored US clinical trials, 6 recruiting.
Crinetics Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Classic Congenital Adrenal Hyperplasia, with 3 trials.
Top-decile sponsor footprint
Crinetics Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
16 total, page 1 of 1
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
NCT06712823
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
NCT05804669
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
NCT07570082
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
NCT05192382
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
NCT04837040
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
NCT04261712
A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
NCT07221084
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
NCT05907291
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
NCT05361668
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
NCT06048887
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
NCT03789656
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
NCT03792555
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 4 |
What is open in the Crinetics Pharmaceuticals pipeline
6 recruiting of 16 indexed (38% open); 6 completed (38%).
Phase mix: 4 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Classic Congenital Adrenal Hyperplasia (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Crinetics Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 16 registered trials and 38% open enrollment, not the therapeutic-area sidebar.
Crinetics Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 38% open enrollment (± trial volume)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 38% recruiting · 8 trials
- American Thrombosis and Hemostasis Network · 38% recruiting · 8 trials
- AskBio · 38% recruiting · 8 trials
- Athletic Greens International · 38% recruiting · 8 trials
Related
What to do with this Crinetics Pharmaceuticals page
16 registered trials is a research-attention snapshot, not an endorsement of Crinetics Pharmaceuticals or any single study.
- 6 of Crinetics Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Classic Congenital Adrenal Hyperplasia is the condition Crinetics Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Classic Congenital Adrenal Hyperplasia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Crinetics Pharmaceuticals pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.